Potent Topoisomerase I Inhibition For Glioma Therapy
有效抑制拓扑异构酶 I 治疗神经胶质瘤
基本信息
- 批准号:6337830
- 负责人:
- 金额:$ 13.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-05-01 至 2002-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (PROVIDED BY APPLICANT): DB-67 is a promising new silatecan
(silylcamptothecin) analog that displays superior blood stability relative to
the FDA-approved camptothecin congeners, topotecan and CPT- 11. DB-67 also
exhibits a high degree of anti-cancer potency both in vitro and in vivo. DB-67 is
a highly lipophilic camptothecin and active lactone levels persist in human tissues
to a much greater degree than existing FDA-approved camptothecins. DB-67 has
been shown by Pollack et al. to be more potent than other camptothecins against
glioblastoma cells; in the same study the agent was found to be highly effective
against intracranially implanted glioblastoma tumors. For this Phase I application
there are two key issues that will be addressed. First, liposomal formulation
studies are required as DB-67 is highly lipophilic and may crystallize at the
site of injection unless properly formulated. Thus, we intend to develop a
lyophilized liposomal DB-67 preparation that displays ideal stability and
microemulsion characteristics upon re-suspension. Secondly, we will test our
lead liposomal formulations in a human glioma xenograft murine model system to
ensure that the DB-67 formulations exhibit the predicted efficacy profile.
DB-67 has already been well explored in vitro and in vivo; thus, the intent of
this Phase I application is to find the best formulation for advancing DB-67 to
clinical trials by thoroughly studying various liposomal formulations.
PROPOSED COMMERCIAL APPLICATION:
Initial FDA approval of comptothecins (topotecan and CPT-11) occurred in 1996. In
1998 their use was expanded by the FDA for new indications. With other campthecins
currently in clinical development, a worldwide market of approximately 1 billion dollars
is anticipated in the near future. Our novel, blood-stable camptothecin, DB-67, described
in this application may present several therapeutic advantages over the campthecin drugs
that are currently used and, accordingly, could eventually control a significant portion of
the campthecin market.
描述(申请人提供):DB-67是一种很有前途的新型硅胶
(硅喜树碱)类似物,其血液稳定性优于
FDA批准的喜树碱同系物拓扑替康和CPT-11.DB-67也
在体外和体内都显示出高度的抗癌效力。DB-67是
高亲脂性喜树碱和活性内酯水平在人体组织中持续存在
比现有FDA批准的喜树碱程度要高得多。DB-67具有
已由波拉克等人展示。比其他喜树碱更有效地对抗
胶质母细胞瘤细胞;在同一项研究中,该药物被发现非常有效
抗脑内植入的胶质母细胞瘤。对于此阶段I应用程序
有两个关键问题将得到解决。第一,脂质体制剂
需要进行研究,因为DB-67是高度亲油的,可能会在
注射部位,除非配方正确。因此,我们打算开发一种
具有理想稳定性和稳定性的冻干脂质体DB-67制剂
复悬浮液的微乳特性。其次,我们将测试我们的
人脑胶质瘤小鼠移植瘤模型系统中的脂质体制剂
确保DB-67配方表现出预期的功效概况。
DB-67已经在体外和体内得到了很好的探索;因此,
这一阶段的应用是寻找最佳配方,将DB-67推进到
通过深入研究各种脂质体配方进行临床试验。
建议的商业应用:
FDA最初批准Comtothecins(拓扑替康和CPT-11)是在1996年。在……里面
1998年,FDA扩大了它们的使用范围,以适应新的适应症。与其他Campthecin
目前处于临床开发阶段,全球市场规模约为10亿美元
预计在不久的将来。我们的新型血液稳定喜树碱DB-67被描述为
在这一应用中可能呈现出比Campthecin药物更多的治疗优势
目前正在使用的,因此最终可能控制很大一部分
坎普特林市场。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.
C.B-17 SCID 小鼠中非脂质体 DB-67 和脂质体 DB-67 的血浆和组织分布。
- DOI:10.1007/s10637-007-9109-9
- 发表时间:2008
- 期刊:
- 影响因子:3.4
- 作者:Zamboni,WilliamC;Jung,LauraL;Strychor,Sandra;Joseph,Erin;Zamboni,BethA;Fetterman,SarahA;Sidone,BrianJ;Burke,ThomasG;Curran,DennisP;Eiseman,JulieL
- 通讯作者:Eiseman,JulieL
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
THOMAS G BURKE其他文献
THOMAS G BURKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('THOMAS G BURKE', 18)}}的其他基金
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
- 批准号:
6978297 - 财政年份:2004
- 资助金额:
$ 13.31万 - 项目类别:
Combinatorial Development of Blood Stable Camptothecins
血液稳定性喜树碱的组合开发
- 批准号:
6333194 - 财政年份:2001
- 资助金额:
$ 13.31万 - 项目类别:
FLUORESCENCE DETECTION OF ANTI CANCER DRUG TOPOTECAN
抗癌药物拓扑替康的荧光检测
- 批准号:
6444723 - 财政年份:2001
- 资助金额:
$ 13.31万 - 项目类别:
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
- 批准号:
6444722 - 财政年份:2001
- 资助金额:
$ 13.31万 - 项目类别:
FLUORESCENCE DETECTION OF ANTI CANCER DRUG TOPOTECAN
抗癌药物拓扑替康的荧光检测
- 批准号:
6315389 - 财政年份:2000
- 资助金额:
$ 13.31万 - 项目类别:
1 & 2 PHOTON FLUORESCENCE IMAGE CAMPTOTHECIN ANTICANCER DRUGS & DRUG CARRIERS
1
- 批准号:
6308191 - 财政年份:2000
- 资助金额:
$ 13.31万 - 项目类别:
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
- 批准号:
6315388 - 财政年份:2000
- 资助金额:
$ 13.31万 - 项目类别:
COMBINATORIAL DEVELOPMENT OF ANTICANCER SILATECANS
抗癌 SILATECANS 的联合开发
- 批准号:
6014855 - 财政年份:2000
- 资助金额:
$ 13.31万 - 项目类别:
PHOTON FLUORESCENCE IMAGE:CAMPTOTHECIN ANTICANCER DRUGS & CARRIER AT TUMOR SITES
光子荧光图像:喜树碱抗癌药物
- 批准号:
6220407 - 财政年份:1999
- 资助金额:
$ 13.31万 - 项目类别:
PREFERENTIAL BINDING OF CARBOXYLATE FORM OF CAMTOTHECIN BY HUMAN SERUM ALBUMIN
喜树碱羧酸盐形式与人血清白蛋白的优先结合
- 批准号:
6122885 - 财政年份:1999
- 资助金额:
$ 13.31万 - 项目类别:
相似海外基金
Self-Assembling Camptothecin Nanofiber Hydrogels as Adjunct Therapy for Intraoperative Treatment of Malignant Glioma
自组装喜树碱纳米纤维水凝胶作为恶性胶质瘤术中治疗的辅助疗法
- 批准号:
10738545 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
Synthesis and modification of intermediates in the camptothecin biosynthetic pathway
喜树碱生物合成途径中间体的合成与修饰
- 批准号:
576453-2022 - 财政年份:2022
- 资助金额:
$ 13.31万 - 项目类别:
Canadian Graduate Scholarships Foreign Study Supplements
Linking metabolic engineering with gene discovery towards biotechnological camptothecin production
将代谢工程与基因发现联系起来,以实现生物技术喜树碱生产
- 批准号:
571673-2021 - 财政年份:2022
- 资助金额:
$ 13.31万 - 项目类别:
Alliance Grants
Engineering cytochrome p450s for the production of hydroxylated camptothecin derivatives
工程化细胞色素 p450 用于生产羟基化喜树碱衍生物
- 批准号:
575889-2022 - 财政年份:2022
- 资助金额:
$ 13.31万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
An integrated approach to camptothecin biosynthesis discovery and engineering
喜树碱生物合成发现和工程的综合方法
- 批准号:
RGPIN-2019-05473 - 财政年份:2022
- 资助金额:
$ 13.31万 - 项目类别:
Discovery Grants Program - Individual
An integrated approach to camptothecin biosynthesis discovery and engineering
喜树碱生物合成发现和工程的综合方法
- 批准号:
RGPIN-2019-05473 - 财政年份:2021
- 资助金额:
$ 13.31万 - 项目类别:
Discovery Grants Program - Individual
Generation of camptothecin structural diversity via biocatalysts
通过生物催化剂产生喜树碱结构多样性
- 批准号:
560578-2020 - 财政年份:2020
- 资助金额:
$ 13.31万 - 项目类别:
University Undergraduate Student Research Awards
An integrated approach to camptothecin biosynthesis discovery and engineering
喜树碱生物合成发现和工程的综合方法
- 批准号:
RGPIN-2019-05473 - 财政年份:2020
- 资助金额:
$ 13.31万 - 项目类别:
Discovery Grants Program - Individual
Investigation of the camptothecin biosynthetic pathway in Fusarium solanii
茄病镰刀菌喜树碱生物合成途径的研究
- 批准号:
553040-2020 - 财政年份:2020
- 资助金额:
$ 13.31万 - 项目类别:
University Undergraduate Student Research Awards
Systems biology approach to unravel biosynthesis and evolution of camptothecin, a potent anti-cancer natural product
系统生物学方法揭示喜树碱(一种有效的抗癌天然产物)的生物合成和进化
- 批准号:
19K16391 - 财政年份:2019
- 资助金额:
$ 13.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists